David A. Knorr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David A. Knorr has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey V. Ravetch
Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, USA
25 shared publications - Juan Carlos Osorio
Memorial Sloan Kettering Cancer Center 3 Immuno-Oncology Program, Department of Medicine New York, New York
21 shared publications - Brian Piening
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, USA
20 shared publications - Alessandra Marino
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA
19 shared publications - Andrew Jones
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA
19 shared publications - Bernard Aloysius Fox
Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center
19 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Elsevier in SSRN Electronic Journal
Spatially Organized Dendritic Cell–t Cell Interactions Are Associated With Response to Cd40 Agonism in Non-muscle Invasive Bladder Cancer
CD40 agonism activates dendritic cells (DCs) and promotes T-cell antitumor immunity, but how tumor immune contexture shapes clinical responses remains unclear. We conducted a phase I study of intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), integrating spatial immune profiling. 2141-V11 was well tolerated, with no dose-limiting toxicities, and the recommended phase 2 dose was 70 mg. Clinical activity was observed, with 40% responses seen at any timepoint and durable benefit (median 20 months). Baseline tumors were immune-inflamed and enriched in tertiary lymphoid structures (TLS), whose abundance and maturity were not associated with response. Instead, response correlated with TLS composition, with enrichment of DC–CXCL13+ CD4+ and CD8+ T cell triads in responders, whereas non-responders showed increased DC-regulatory T cell proximity. These findings identify spatially organized DC–T cell interactions as a determinant of response to CD40 agonism in BCG-unresponsive NMIBC.
- 14 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSpatially Organized Dendritic Cell–t Cell Interactions Are Associated With Response to Cd40 Agonism in Non-muscle Invasive Bladder Cancer
CD40 agonism activates dendritic cells (DCs) and promotes T-cell antitumor immunity, but how tumor immune contexture shapes clinical responses remains unclear. We conducted a phase I study of intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), integrating spatial immune profiling. 2141-V11 was well tolerated, with no dose-limiting toxicities, and the recommended phase 2 dose was 70 mg. Clinical activity was observed, with 40% responses seen at any timepoint and durable benefit (median 20 months). Baseline tumors were immune-inflamed and enriched in tertiary lymphoid structures (TLS), whose abundance and maturity were not associated with response. Instead, response correlated with TLS composition, with enrichment of DC–CXCL13+ CD4+ and CD8+ T cell triads in responders, whereas non-responders showed increased DC-regulatory T cell proximity. These findings identify spatially organized DC–T cell interactions as a determinant of response to CD40 agonism in BCG-unresponsive NMIBC.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcÎłR mice bearing B16 or MCA-205 tumors
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcÎłR mice bearing B16 or MCA-205 tumors
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcÎłR mice bearing B16 or MCA-205 tumors
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Expression profile of hCTLA-4 in humanized CTLA-4/FcÎłR mice bearing B16 or MCA-205 tumors
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered human anti-CTLA-4 antibodies
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered human anti-CTLA-4 antibodies
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Primers for site-directed mutagenesis
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from FcÎłRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Antitumor activity of Fc-engineered murine anti-CCR8 antibodies